What is the best approach for screen-detected low volume cancers?-The case for observation

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 5, 2008, Pages 495-499

  Klotz, Laurence ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Active surveillance; Localized favorable risk disease management; Prostate cancer; Watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SCREENING; CLINICAL STUDY; CONSERVATIVE TREATMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; GLEASON SCORE; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; RISK MANAGEMENT;

CLINICAL TRIALS AS TOPIC; HUMANS; MALE; MASS SCREENING; OBSERVATION; PROSTATIC NEOPLASMS;

EID: 50649103058     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.03.003     Document Type: Review

References (33)

1. Welch H.G., Schwartz L.M., and Woloshin S. Prostate-specific antigen levels in the United States: Implications of various definitions for abnormal. J Natl Cancer Inst 97 15 (2005) 1132-1137
2. Sakr W.A., Haas G.P., Cassin B.F., et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 150 (1993) 379-385
3. Jemal A., Tiwari R.C., Murray T., et al. Cancer Statistics, 2004. CA Cancer J Clin 54 (2004) 8-29
4. Etzioni R., Penson D.F., Legler J.M., et al. Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94 (2002) 981-990
5. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
6. Albertsen P., Hanley J.A., and Fine J. Twenty-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005) 2095-2101
7. Albertsen P.C., Hanley J.A., Barrows G.H., et al. Prostate cancer and the Will Rogers phenomenon. Natl Cancer Inst 97 (2005) 1248-1253
8. Hanash K.A., Utz D.C., Cook E.N., et al. Carcinoma of the prostate: A 15-year follow-up. J Urol 107 (1972) 450-453
9. Johansson J.E., Holmberg L., Johansson S., et al. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 277 (1997) 467-471
10. Lerner S.P., Seale-Hawkins C., Carlton Jr. C.E., et al. The risk of dying of prostate cancer in patients with clinically localized disease. J Urol 146 (1991) 1040-1045
11. Handley R., Carr T.W., Travis D., et al. Deferred treatment for prostate cancer. Br I Urol 62 (1988) 249-253
12. Adolfsson J., Carstensen J., and Löwhagan T. Deferred treatment in clinically localized prostate carcinoma. Brit J Urol 69 (1992) 183-187
13. Waaler G., and Stenwig A.E. Prognosis of localized prostatic cancer managed by "watch and wait" policy. Br J Urol 72 (1993) 214-219
14. Whitmore Jr. W.F., Warner J.A., and Thompson Jr. I.M. Expectant management of localized prostatic cancer. Cancer 67 (1991) 1091-1096
15. George N. Natural history of localized prostatic cancer managed by conservative therapy alone. Lancet 1 (1988) 494-497
16. Aus G., Hugosson I., and Norlén L. Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 154 (1995) 460-465
17. Sandblom G., Dufmats M., and Varenhorst E. Long-term survival in a Swedish population-based cohort of men with prostate cancer. Urology 56 (2000) 442-447
18. Parker C. Active surveillance: Towards a new paradigm in the management of early prostate cancer. Lancet Oncol 5 (2004) 101-106
19. Parker C. Active surveillance: An individualized approach to early prostate cancer. BJU Int 92 (2003) 2-3
20. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
21. Presti Jr. J.C. Prostate biopsy: How many cores are enough?. Urol Oncol 21 (2003) 135-140
22. Draisma G., Boer R., Otto S.J., et al. Lead times and overdetection due to PSA screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95 12 (2003) 868-878
23. Törnblom M., Eriksson H., Franzén S., et al. Lead time associated with screening for prostate cancer. Int J Cancer 108 1 (2004) 122-129
24. Choo R., Klotz L., Danjoux C., et al. Feasibility study: Watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 167 (2002) 1664-1669
25. Choo R., DeBoer G., Klotz L., et al. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biology Phys 50 (2001) 615-620
26. Klotz L. Active surveillance for prostate cancer: For whom?. J Clin Oncol 23 32 (2005) 8165-8169
27. Bill-Axelson A., and Holmberg L. Radical prostatectomy vs. watchful waiting (update). N Engl J Med 352 19 (2005) 1977-1984
28. Steineck G., Helgesen F., Adolfsson J., et al., Scandinavian Prostatic Cancer Group Study Number 4. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 347 11 (2002) 790-796
29. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
30. Chodak G. The role of watchful waiting in the management of localized prostate cancer. J Urol 152 (1994) 1766-1768
31. Egawa S., Arai Y., Tobisu K., et al. Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis 3 (2000) 269-274
32. McLaren D.B., McKenzie M., Duncan G., et al. Watchful waiting or watchful progression?. Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer 82 (1998) 342-348
33. D'Amico A.V., Chen M.H., Roehl K.A., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 2 (2004) 125-135